

Stefania Grimaudo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8724820/publications.pdf>

Version: 2024-02-01

113
papers

4,958
citations

87886

38
h-index

98792

67
g-index

114
all docs

114
docs citations

114
times ranked

7296
citing authors

#	ARTICLE	IF	CITATIONS
1	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015, 61, 506-514.	7.3	424
2	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , 2015, 63, 705-712.	3.7	309
3	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. <i>Journal of Internal Medicine</i> , 2018, 283, 356-370.	6.0	256
4	Synthesis and Biological Evaluation of Resveratrol and Analogues as Apoptosis-Inducing Agents. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3546-3554.	6.4	205
5	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	3.3	193
6	Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-Inducing Activity in HL60 and in MDR Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 723-736.	6.4	143
7	Pterostilbene and 3- β -hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 1709-1726.	2.8	142
8	Synthesis and Biological Evaluation of 2- and 3-Aminobenzo[b]thiophene Derivatives as Antimitotic Agents and Inhibitors of Tubulin Polymerization. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2273-2277.	6.4	131
9	Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <i>Gastroenterology</i> , 2016, 151, 130-139.e2.	1.3	130
10	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	2.5	112
11	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 682-690.	3.7	106
12	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3.	4.4	102
13	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24.	3.7	98
14	Design, synthesis, and biological evaluation of thiophene analogues of chalcones. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 5367-5376.	3.0	93
15	Synthesis and Biological Evaluation of 1-Methyl-2-(3,4,5-trimethoxybenzoyl)-3-aminoindoles as a New Class of Antimitotic Agents and Tubulin Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1464-1468.	6.4	90
16	Heterocycle-Containing Retinoids. Discovery of a Novel Isoxazole Arotinoid Possessing Potent Apoptotic Activity in Multidrug and Drug-Induced Apoptosis-Resistant Cells. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2308-2318.	6.4	88
17	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012, 56, 1356-1362.	3.7	82
18	Identification of Biphenyl-Based Hybrid Molecules Able To Decrease the Intracellular Level of Bcl-2 Protein in Bcl-2 Overexpressing Leukemia Cells. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6936-6940.	6.4	79

#	ARTICLE	IF	CITATIONS
19	Interferon lambda 4 rs368234815 T>G variant is associated with liver damage in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 66, 1885-1893.	7.3	75
20	Identification of a Terphenyl Derivative that Blocks the Cell Cycle in the G0~G1 Phase and Induces Differentiation in Leukemia Cells. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3012-3018.	6.4	74
21	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. <i>Liver International</i> , 2018, 38, 2060-2068.	3.9	72
22	Insulin-Like Growth Factor-I, Inflammatory Proteins, and Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E304-E308.	3.6	69
23	Stilbene-based anticancer agents: Resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3245-3248.	2.2	68
24	Design, synthesis and structure~activity relationship of 2-(3~4~5-trimethoxybenzoyl)-benzo[b]furan derivatives as a novel class of inhibitors of tubulin polymerization. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6862-6871.	3.0	68
25	Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. <i>Cancer Letters</i> , 2008, 265, 289-297.	7.2	66
26	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2013, 8, e74089.	2.5	59
27	Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. <i>International Immunopharmacology</i> , 2001, 1, 1765-1776.	3.8	53
28	Synthesis and Biological Evaluation of 2-(3~4~5-Trimethoxybenzoyl)-3-Amino 5-Aryl Thiophenes as a New Class of Tubulin Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6425-6428.	6.4	53
29	Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins. <i>Thrombosis Research</i> , 2008, 123, 194-199.	1.7	51
30	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Liver International</i> , 2019, 39, 1742-1754.	3.9	51
31	The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. <i>Cell Death and Differentiation</i> , 1998, 5, 735-742.	11.2	49
32	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 486-493.	2.0	49
33	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. <i>Haematologica</i> , 2012, 97, 679-686.	3.5	46
34	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	2.8	43
35	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2660-2669.	3.6	42
36	Structure~Activity Relationship Studies of Novel Heteroretinoids: Induction of Apoptosis in the HL-60 Cell Line by a Novel Isoxazole-Containing Heteroretinoid. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4961-4969.	6.4	41

#	ARTICLE	IF	CITATIONS
37	The UCP2 δ 66G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 1574-1580.	3.9	41
38	Synthesis and biological evaluation of 2-(3,4,5-trimethoxybenzoyl)-3-N,N-dimethylamino benzo[b]furan derivatives as inhibitors of tubulin polymerization. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 8419-8426.	3.0	40
39	Substituted 2-(3,4,5-trimethoxybenzoyl)-benzo[b]thiophene derivatives as potent tubulin polymerization inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5114-5122.	3.0	40
40	3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: A novel class of potent tubulin inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 4151-4167.	5.5	40
41	Novel Terphenyls and 3,5-Diaryl Isoxazole Derivatives Endowed with Growth Supporting and Antiapoptotic Properties. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4796-4803.	6.4	38
42	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018, 2, 666-675.	4.3	38
43	A convenient synthesis of unsymmetrically substituted terphenyls of biologically active stilbenes via a double Suzuki cross-coupling protocol. <i>Tetrahedron Letters</i> , 2003, 44, 3005-3008.	1.4	32
44	SARS-CoV-2 Viral Load, IFN γ Polymorphisms and the Course of COVID-19: An Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3315.	2.4	32
45	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 311-317.e1.	4.4	30
46	Synthesis of novel antimetabolic agents based on 2-amino-3-aryl-5-(hetero)arylethynyl thiophene derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2746-2751.	2.2	29
47	Vitamin D Levels and IL28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2012, 17, 823-831.	1.0	29
48	Studies on the Apoptotic Activity of Natural and Synthetic Retinoids: A Discovery of a New Class of Synthetic Terphenyls That Potently Support Cell Growth and Inhibit Apoptosis in Neuronal and HL-60 Cells. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4293-4299.	6.4	28
49	Synthesis, antiproliferative activity, and mechanism of action of a series of 2-[(2E)-3-phenylprop-2-enoyl]amino}benzamides. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2786-2796.	5.5	28
50	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 193-200.	3.6	28
51	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011, 43, 404-410.	0.9	27
52	Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4568-4574.	2.2	27
53	The "Janus" Role of C/EBPs Family Members in Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4308.	4.1	27
54	Organometallic complexes with biological molecules, IV. Di- and tri-organotin(IV) amoxicillin derivatives: Solid-state and solution-phase spectroscopic investigations. <i>Applied Organometallic Chemistry</i> , 1995, 9, 227-239.	3.5	26

#	ARTICLE	IF	CITATIONS
55	Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines. <i>British Journal of Pharmacology</i> , 2001, 133, 306-314.	5.4	26
56	<i>PCSK9</i> rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021, 41, 321-332.	3.9	26
57	Chemically modified tetracyclines induce cytotoxic effects against J774 tumour cell line by activating the apoptotic pathway. <i>International Immunopharmacology</i> , 2003, 3, 63-73.	3.8	24
58	Synthesis and biological evaluation of 2-amino-3-(3,4,5-trimethoxybenzoyl)-6-substituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine derivatives as antimitotic agents and inhibitors of tubulin polymerization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5041-5045.	2.2	23
59	Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 98-104.	5.5	23
60	Synthesis and antiproliferative activity of 3-amino-N-phenyl-1H-indazole-1-carboxamides. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 165-178.	5.5	21
61	Reaction of amino substituted heterocycles with one heteroatom in a five-membered ring as enamines. A revision. <i>Journal of Heterocyclic Chemistry</i> , 1995, 32, 985-989.	2.6	19
62	Effects of Pimozide Derivatives on pSTAT5 in K562 Cells. <i>ChemMedChem</i> , 2017, 12, 1183-1190.	3.2	19
63	Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD. <i>Nutrients</i> , 2021, 13, 2952.	4.1	19
64	Synthesis of substituted 3-amino-N-phenyl-1H-indazole-1-carboxamides endowed with antiproliferative activity. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 168-174.	5.5	18
65	<i>PNPLA3</i> rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 939-948.	3.7	18
66	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , 2020, 12, 2132.	3.7	18
67	Methylenetetrahydrofolate reductase mutation in subjects with abdominal aortic aneurysm subdivided for age. <i>Clinical Hemorheology and Microcirculation</i> , 2006, 34, 421-6.	1.7	18
68	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , 2020, 40, 2820-2827.	3.9	17
69	Role of IL28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. <i>Journal of Viral Hepatitis</i> , 2013, 20, 113-121.	2.0	16
70	Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 604.	3.5	16
71	<i>TM6SF2</i> rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016, 36, 198-204.	3.9	15
72	A Natural-Like Synthetic Small Molecule Impairs Bcr-Abl Signaling Cascades and Induces Megakaryocyte Differentiation in Erythroleukemia Cells. <i>PLoS ONE</i> , 2013, 8, e57650.	2.5	15

#	ARTICLE	IF	CITATIONS
73	PSD3 downregulation confers protection against fatty liver disease. <i>Nature Metabolism</i> , 2022, 4, 60-75.	11.9	15
74	Programmed cell death (PCD) associated with the stilbene motif of arotinoids: discovery of novel apoptosis inducer agents possessing activity on multidrug resistant tumor cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 2669-2673.	2.2	13
75	Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 973-978.	2.8	13
76	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. <i>Cells</i> , 2019, 8, 666.	4.1	13
77	3-Triazenoindoles. Synthesis and antileukemic activity. <i>European Journal of Medicinal Chemistry</i> , 1994, 29, 889-891.	5.5	11
78	Reactivity of aminopyrroles: Protonation. <i>Journal of Heterocyclic Chemistry</i> , 1996, 33, 161-168.	2.6	11
79	Identification and cloning of a umu locus in <i>Streptomyces coelicolor</i> A3(2). <i>Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1991, 262, 183-188.	1.1	10
80	Synthesis and Pharmacology of 6-Substituted Benzotropines: Discovery of Novel Dopamine Uptake Inhibitors Possessing Low Binding Affinity to the Dopamine Transporter. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3337-3343.	6.4	10
81	Antiproliferative Agents That Interfere with the Cell Cycle at the G ₁ 'S Transition: Further Development and Characterization of a Small Library of Stilbene-Derived Compounds. <i>ChemMedChem</i> , 2008, 3, 345-355.	3.2	10
82	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158765.	2.4	10
83	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1979-1981.	4.4	10
84	Polycondensed Nitrogen Heterocycles. Part 26. Aminopyrrolo[1,2-f]phenanthridines by Decomposition and Cyclization of 2-Aryl-1-(3-azidophenyl)pyrroles. <i>Heterocycles</i> , 1994, 37, 1549.	0.7	10
85	Synthesis of 3-Triazeno-pyrroles. <i>Synthetic Communications</i> , 1993, 23, 1627-1631.	2.1	7
86	Pig liver esterase (PLE)-mediated resolution of N-substituted 4-benzoyloxy-3-carbomethoxypiperidines: a convenient preparation of 4-hydroxy- and 4-benzoyloxy-3-carbomethoxypiperidines in enantiomerically pure form. <i>Tetrahedron: Asymmetry</i> , 2000, 11, 4397-4405.	1.8	7
87	Retinoic acid and analogs as potent inducers of differentiation and apoptosis. New promising chemopreventive and chemotherapeutic agents in oncology. <i>Pure and Applied Chemistry</i> , 2001, 73, 1437-1444.	1.9	7
88	The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells. <i>Anti-Cancer Drugs</i> , 2013, 24, 384-393.	1.4	6
89	Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 39-52.	5.5	6
90	rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719.	3.9	6

#	ARTICLE	IF	CITATIONS
91	A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 1032-1044.	4.3	6
92	STAT5 and STAT5 Inhibitors in Hematological Malignancies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 19, 2036-2046.	1.7	5
93	Genetic Predisposition to Thrombophilia in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, e25-e29.	2.2	4
94	Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. <i>Hepatitis Monthly</i> , 2016, 16, e31681.	0.2	4
95	Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis. <i>Anticancer Research</i> , 2004, 24, 851-7.	1.1	4
96	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	3.9	4
97	Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms. <i>Digestive and Liver Disease</i> , 2005, 37, 446-450.	0.9	3
98	MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2016, 48, e7-e8.	0.9	3
99	FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2019, 51, e26.	0.9	3
100	Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines. <i>British Journal of Pharmacology</i> , 2002, 135, 1588-1588.	5.4	1
101	Rs4374383 single nucleotide polymorphism of MERTK gene influences the development of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis. <i>Digestive and Liver Disease</i> , 2013, 45, e367.	0.9	1
102	SAT-223-AA genotype of the deSNP rs6726639 of gene MERTK (MER Tyrosine Kinase) is associated with development of hepatocellular carcinoma after hepatitis C virus clearance. <i>Journal of Hepatology</i> , 2019, 70, e728.	3.7	1
103	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , 2020, 40, 530-538.	3.9	1
104	MERTK rs4374383 AA genotype is associated with a lower prevalence of severe hepatic steatosis in non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2014, 46, e2.	0.9	0
105	THU-334-PNPLA3 rs738409 C >G variant predicts liver-related events and death in non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2019, 70, e307.	3.7	0
106	THU-335-FXR rs35724 C >G variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2019, 70, e307-e308.	3.7	0
107	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Digestive and Liver Disease</i> , 2019, 51, e4.	0.9	0
108	Effects of HCV eradication by DAA on oxidative stress parameters in patients with chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2019, 51, e59.	0.9	0

#	ARTICLE	IF	CITATIONS
109	PNPLA3 rs738409 C>G variant predicts occurrence of liver-related events and death in non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2019, 51, e5-e6.	0.9	0
110	Changes in 13C-aminopyrine breath test predict liver-related events and death in patients with HCV-related previous decompensated child A5 or child A6 to B cirrhosis who achieve SVR after DAA therapy. <i>Digestive and Liver Disease</i> , 2019, 51, e68.	0.9	0
111	PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2020, 52, e8.	0.9	0
112	Novel Stilbene-Based Antileukemic Agents Active in P-Glycoprotein Expressing and Apoptosis-Resistant Acute Leukaemia Cell Lines.. <i>Blood</i> , 2005, 106, 4436-4436.	1.4	0
113	<i>rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0